Guizhou Kekai Medicine Co., Ltd. announced that it will receive CNY 461,450,506.01 in an equity round of funding on November 6, 2021. The transaction will include participation from returning investor Guizhou Xinbang Pharmaceutical Co., Ltd. Pursuant to the transaction the registered capital of the company will be CNY 2,200,000,000. The transaction has been approved by investors 5th session of it's 8th directorate.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
4.05 CNY | +0.50% | +2.27% | -8.78% |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-8.78% | 1.06B | |
+43.25% | 6.3B | |
-15.08% | 4.44B | |
-6.70% | 3.27B | |
+5.47% | 3.16B | |
+0.76% | 2.58B | |
+47.75% | 1.96B | |
-5.08% | 1.73B | |
+2.05% | 1.68B | |
-7.08% | 1.63B |
- Stock Market
- Equities
- 002390 Stock
- News Guizhou Xinbang Pharmaceutical Co., Ltd.
- Guizhou Kekai Medicine Co., Ltd. announced that it expects to receive CNY 461.450506 million in funding from Guizhou Xinbang Pharmaceutical Co., Ltd.